HOME : SITE MAP : HELP : CONTACT US : MEDIA : MISSION : EN ESPAÑOL

TREDE LAB

Research

DiGeorge Project

Immune Deficiency

Autoimmunity

Leukemia

Innate Immunity

Methods and Technology

--Transplantation

--TILLING

--Multispectral Imaging

--Morpholinos

--Mapping

--Injections

--Genetic Screens

--FACS

Post Doc Opps

Lab Members

Publications

Local Links

Zebrafish Links

Collaborators

Zebrafish Immunology

Zebrafish Facility

T Cell Mutants

TILLING

An alternative to standard mammalian gene targeting has recently yielded
the first mutant fish by a reverse genetics approach. This approach, which is also known as TILLING (Targeting Induced Local Lesions In Genomes), had been pioneered in other organisms such as Arabidopsis. The method consists of identifying F1 males from standard ethylnitrosourea (ENU) screens that harbor heterozygous mutations in the gene of interest (see Figure). For this, a library of DNA from 2,000-4,000 F1 males is generated in parallel with a library of matching cryopreserved sperm samples. Genomic DNA from the sperm donors is arrayed for high-throughput mutation screening by PCR and sequencing of the exons of the gene of interest. Alternatively, pooled DNA from 4-8 donors can be screened for mutations using the CelI endonuclease. Individuals from positive pools are then sequenced to identify the nucleotide change. Lines of fish carrying an inactivating mutation are then established by thawing the corresponding sperm samples and performing in vitro fertilization. Inbreeding of heterozygous offspring will produce homozygous mutants for the gene of interest, and are then available for phenotypic analysis, enhancer- and suppressor screens.

Last Modified: Friday, January 28, 2005

footer

HELP  :  CONTACT US  :   DISCLOSURE  :   PRIVACY STATEMENT  :  EN ESPAÑOL

Huntsman Cancer Institute operates a hospital-based patient care center in association with
the Health Sciences Center at the University of Utah.

University of Utah disclaimer.

Copyright © 2009, all rights reserved, Huntsman Cancer Institute.